We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
planarTECH is an engineering company founded in 2014 as a provider of process equipment for the growth and characterisation of graphene and other emerging 2D materials. Its core product line is the planarGROW Chemical Vapor (CVD) system. The company has the ability to deliver scalable production systems that allow lower-cost production of graphene in comparison to other options currently available in the market. Moreover, from 2014 to 2019, the company’s cumulative revenues exceeded £5 million. The company's products have been installed and used by faculties and students at prestigious universities like Stanford University (USA), IIT- Bombay (India), Deakin University (Australia), and many others. From the investment, the company will utilise 45% as working capital, 30% in Capital Expenditures (CAPEX), 15% in R&D and 10% in hiring additional staff.

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £425,061
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Cell Guidance Systems is developing a technology called PODS (Polyhedrin Delivery System) PODS allow them to deliver therapeutic proteins accurately and over long periods of time. PODS enable proteins to treat diseases, such as Parkinson’s disease and osteoarthritis.
days to go: Expired investment: £836,370
FloatWind manufactures mass-produced floating offshore wind turbines. It seeks to disrupt the £20 billion offshore wind energy market. The company argues that conventional offshore wind farms, installed at sea, use expensive and slow installation methods that are also dangerous to the marine environment. It further stresses that the high cost of installation is often borne by the consumer. FloatWind asserts that its business model is different. The company claims to build its products on land and then floats its ready-to-float turbines out to sea. The company points out that this reduces environmental damage, substantially reduces costs, and makes offshore wind energy cheaper. FloatWind was selected for a 6-month UK Innovate Edge business mentoring programme and appeared for SetSquared Business Mentoring Seminar in May 2021. The company has 3,000+ followers on LinkedIn. FloatWind states it will use the investment for product development, expanding its team, IP protection, promoting marketing and PR, and boosting its manufacturing capabilities.
days to go: Expired investment: £311,497
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Tourniglo is a company that has come up with a unique two in one emergency tourniquet with a built-in torch. The innovation was driven by an identified need within the emergency services to provide an immediately available light source in dim-lighted areas when undertaking a patient or casualty eye examination as well as for military and close protection staff who might need to inject intravenous medication in rural areas. The global tourniquet systems market is expected to reach half a billion US dollars by 2025. The company aims to launch the production of its first product. Additionally, Tourniglo has been featured on the BBC website and has won various medals at international events, including a 'Gold Medal' at the World Invention Awards. The company requires investment to set-up manufacturing, packaging and distribution, and grow sales for the first year of commercialisation.
days to go: Expired investment: £21,414
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
'Revolution Race Cars' is the brainchild of a team of British designers, engineers, and industry specialists. The company has produced an all-new race car: Revolution A-One that challenges not only the status quo but also changes the postcode. The car is created after eighteen months of R&D, rigorous selection, and 4,000 miles of extreme testing of Revolution's suppliers and partners. The official production of Revolution A-One started in May 2019, and its sales have already been recorded in three countries. With the proceeds, the company will optimise its production cycle for future expansion.
days to go: Expired investment: £392,220
Ultramed are a health tech company, placing patient experience and innovation at the forefront. They operate a suite of cloud based pre operative products by combining clinical NHS operative experience. The aim is to reduce costs increase health care resources.
days to go: Expired investment: £317,540
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph